Halozyme Therapeutics Inc
NASDAQ:HALO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
33.68
64.42
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
HALO Price Targets Summary
Halozyme Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for HALO is 63.69 USD with a low forecast of 50.5 USD and a high forecast of 78.75 USD.
HALO Last Price Targets
Halozyme Therapeutics Inc
The latest public price target was made on Nov 15, 2024 by Joseph Catanzaro from Piper Sandler , who expects HALO stock to rise by 11% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.
Analyst | Price Target | Date | Article |
---|---|---|---|
Joseph Catanzaro
Piper Sandler
|
52
USD
Upside 11% |
1 month ago
Nov 15, 2024
|
Piper Sandler Reiterates Neutral Rating on Halozyme Therapeutics (HALO)
StreetInsider
|
Mohit Bansal
Wells Fargo
|
58
USD
Upside 24% |
6 months ago
Jun 7, 2024
|
Halozyme Therapeutics (HALO) PT Raised to $58 at Wells Fargo
StreetInsider
|
Joseph Catanzaro
Piper Sandler
|
51
USD
Upside 9% |
6 months ago
Jun 7, 2024
|
Halozyme downgraded to Neutral after rally at Piper Sandler
TheFly
|
Mitchell Kapoor
H.C. Wainwright
|
65
USD
Upside 38% |
6 months ago
Jun 7, 2024
|
Halozyme Therapeutics (HALO) PT Raised to $65 at H.C. Wainwright
StreetInsider
|
Corinne Jenkins
Goldman Sachs
|
44
USD
Downside 6% |
6 months ago
Jun 6, 2024
|
Halozyme price target raised to $44 from $41 at Goldman Sachs
TheFly
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is HALO's stock price target?
Price Target
63.69
USD
According to Wall Street analysts, the average 1-year price target for HALO is 63.69 USD with a low forecast of 50.5 USD and a high forecast of 78.75 USD.
What is Halozyme Therapeutics Inc's Revenue forecast?
Projected CAGR
19%
For the last 8 years the compound annual growth rate for Halozyme Therapeutics Inc's revenue is 25%. The projected CAGR for the next 4 years is 19%.
What is Halozyme Therapeutics Inc's Operating Income forecast?
Projected CAGR
33%
The compound annual growth rate of Halozyme Therapeutics Inc's operating income for the next 4 years is 33%.
What is Halozyme Therapeutics Inc's Net Income forecast?
Projected CAGR
38%
The compound annual growth rate of Halozyme Therapeutics Inc's net income for the next 4 years is 38%.